Reactivation of HBV infection in low grade lymphoma patient.
Reactivation of hepatitis B virus is a complication of chronic or HBV infection in patients with malignancies, especially hematological disorders, under cytotoxic or immunosuppressive therapy. The immunosuppression favors HBV replication with the massive infection of hepatocytes. Once immunity is restored when chemotherapy therapy is discontinued, a rapid, immune-mediated destruction of the infected hepatocytes ensues, clinically manifested as hepatitis, liver failure or even death. We report a case of HBV reactivation in a patient with B cells non-Hodgkin lymphoma, with HBsAg negative and protective titre of anti-HBs, after 5 months of combined chemotherapy. Currently, there are no data to support routine pre-emptive anti-HBV therapy in patients with negative HBsAg and undetectable viremia before the initiation of chemotherapy. The case presented in this paper is included in the group of patients that is studied in LIMFOVIR Grant (convention no 41012/2007). This research grant is funded by the National Center of Programs Management, program 4 - Partnerships in Priority Fields. The grant is coordinated by the National Institute of Infectious Diseases Prof. Dr. Matei Bals, Bucharest. The grant team include also the Emergency University Hospital Bucharest, Hematology Department, the "Carol Davila" University of Medicine and Pharmacy, Bucharest, the "Victor Babeş" National Institute of Research and Development, the Institute of Electrotechnical Research, Bucharest and the Polytechnic University, Bucharest. The manager of the grant is Associated Professor dr. Victoria Aramă.
"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest. ralsan@gmail.com
Victoria
V
Aramă
Daniela
D
Munteanu
Ioana
I
Olaru
Mihaela
M
Rădulescu
Raluca
R
Mihăilescu
Ana-Maria
AM
Vlădăreanu
Minodora
M
Onisâi
Anamaria
A
Vintilescu
Camelia
C
Dobrea
M
M
Olariu
S S
SS
Aramă
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000502:physiology*; D019694:Hepatitis B, Chronic / Q000097:blood / Q000276:immunology*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D008875:Middle Aged; D015166:Monitoring, Immunologic; D016896:Treatment Outcome; D014775:Virus Activation / Q000187:drug effects*
D000970:Antineoplastic Agents; D006514:Hepatitis B Surface Antigens